Keyword Analysis & Research: ticagrelor pad
Keyword Research: People who searched ticagrelor pad also searched
Search Results related to ticagrelor pad on Search Engine
Examining Use of Ticagrelor in Peripheral Arterial Disease ...
Nov 13, 2016 · Among patients with symptomatic PAD, ticagrelor was not superior to clopidogrel in preventing major adverse cardiac events. Acute limb ischemia and major bleeding were also similar between treatment groups. Study drug discontinuation occurred at a higher frequency in the ticagrelor …
DA: 69 PA: 88 MOZ Rank: 48
Ticagrelor in Peripheral Artery Disease Endovascular ...
The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study (TI-PAD) evaluated the role of ticagrelor … There is limited evidence to guide clinical decision-making for antiplatelet therapy in peripheral artery disease (PAD) …
DA: 1 PA: 74 MOZ Rank: 30
THEMIS-PAD: Ticagrelor Reduces Risk of Limb Events in ...
Aug 29, 2020 · The very high risk of limb events in patients with PAD, on top of CAD and T2D, and reductions with ticagrelor of about 50% for major adverse limb events and 20% for peripheral …
DA: 62 PA: 42 MOZ Rank: 10
Ticagrelor versus Clopidogrel in Symptomatic Peripheral ...
In this randomized trial involving 13,885 patients with symptomatic peripheral artery disease (PAD), ticagrelor was not shown to be superior to clopidogrel for the reduction of cardiovascular...
DA: 1 PA: 24 MOZ Rank: 38
How does ticagrelor reduce risk of limb events?
The very high risk of limb events in patients with PAD, on top of CAD and T2D, and reductions with ticagrelor of about 50% for major adverse limb events and 20% for peripheral revascularization suggests long-term benefit with the drug for preventing cardiovascular and limb events, researchers said.
DA: 44 PA: 29 MOZ Rank: 92
Which is better ticagrelor or clopidogrel monotherapy?
Data from previous trials have suggested that patients receiving clopidogrel monotherapy had a lower risk of cardiovascular events than those receiving aspirin. We wanted to compare clopidogrel with ticagrelor, a potent antiplatelet agent, in patients with peripheral artery disease.
DA: 76 PA: 90 MOZ Rank: 73
How is ticagrelor used to treat heart disease?
In patients with a myocardial infarction more than 1 year previously, treatment with ticagrelor significantly reduced the risk of cardiovascular death, myocardial infarction, or stroke and increased the risk of major bleeding. (Funded by AstraZeneca; PEGASUS-TIMI 54 ClinicalTrials.gov number, NCT01225562.)
DA: 64 PA: 93 MOZ Rank: 89
How is ticagrelor used in the Themis trial?
They also evaluated the efficacy of adding ticagrelor to aspirin to reduce limb ischemic events and whether this effect was similar in patients with and without PAD. During the THEMIS trial, limb ischemic events were prospectively reported to an electronic data capture system.
DA: 75 PA: 39 MOZ Rank: 64